Key Dates

Related Announcements

RFA-DA-22-040 - High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)

Issued by

National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this notice is to inform applicants of a correction to the Application and Submission Information for RFA-DA-22-040 - High Priority HIV and Substance Use Research (R01 Clinical Trial Optional).   

The following text has been removed.

Section IV. Application and Submission Information

Requests of $500,000 or more for direct costs in any year

Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application and follow the Policy on the Acceptance for Review of Unsolicited Applications that Request $500,000 or More in Direct Costs as described in the SF424 (R&R) Application Guide.

All other aspects of the NOFO remain the same.

Inquiries

Please direct all inquiries to:

Vasundhara Varthakavi, DVM, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-2146
Email: vasundhara.varthakavi@nih.gov

Richard A. Jenkins Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-1923
Email: jenkinsri@nida.nih.gov

John Satterlee Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-435-1020
Email: satterleej@nida.nih.gov

Raul N. Mandler Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-480-2541 
Email: mandlerr@mail.nih.gov